Limitations in the Evidence Base for Bruton Tyrosine Kinase Inhibitors in Chronic Spontaneous Urticaria

Abstract

Get full access to this article

View all access options for this article.

References

Cevallos-Cueva

Ghanem

Kuceki

, et al. Bruton’s tyrosine kinase inhibitors for chronic spontaneous urticaria: a systematic review and meta-analysis. J Cutan Med Surg. 2026;2026:Article 12034754261418239. doi:10.1177/12034754261418239

Metz

Sussman

Gagnon

, et al. Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial. Nat Med. 2021;27(11):1961-1969. doi:10.1038/s41591-021-01537-w

Altayf

Gadelmawla

Lateiresh

Khasawneh

Elhadi

. Efficacy and safety of remibrutinib in chronic spontaneous urticaria: a systematic review and meta-analysis of data up to 24 weeks. Review. Arch Dermatol Res. 2026;318(1):4. doi:10.1007/s00403-025-04461-y